INTERCEPT PHARMACEUTICALS IN (ICPT) Stock News
NASDAQ:ICPT - Nasdaq - US45845P1084 - Common Stock - Currency: USD
ICPT Latest News, Press Relases and Analysis
Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBCPrecedent-setting submission includes data from...
CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst
Gilead's acquisition of CymaBay Therapeutics for $4.3 billion strengthens its liver disease portfolio. Analysts see potential in seladelpar's impact on PBC and pruritus, projecting peak sales of $800 million.
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”)...
Top 5 Health Care Stocks That Should Keep You Up At Night
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Why Intercept Pharmaceuticals Stock Is Skyrocketing Today
Intercept is on track to be acquired by Alfasigma at a significant premium compared to recent prices.
Why Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today?
Although Intercept Pharmaceuticals popped higher on a buyout deal, many stakeholders of ICPT stock are left wondering what might have been.
Stocks to Sell: 7 Overbought Companies You Ought to Dump Right Now
Overbought stocks are an early indication of a potential correction on a stock; act now if you hold these stocks.
Intercept stock drops amid report from European Medicines Agency on Ocaliva (NASDAQ:ICPT)
ntercept Pharmaceuticals quickly dropped 3% amid a new report from the European Medicines Agency.
Why CymaBay Therapeutics Stock Is Jumping Today
The momentum continues after CymaBay reported great clinical results on Thursday.
Mentions: CBAY
Intercept failed NASH candidate precipitated Alfasigma acquisition
Intercept Pharmaceuticals' failure in developing Ocaliva for NASH led to an acquisition as its best outcome. Read more here.
Canaccord cuts Intercept to hold, calls Alfasigma deal
Canaccord downgraded Intercept Pharmaceuticals to hold, calling its merger deal with Alfasigma for $19 per share the best outcome for the company. Read more here.
Intercept Pharma unlikely to see rival offers, other roadblocks, analysts say
Intercept Pharmaceutical is unlikely to attract other bidders after agreeing to a $19 per share sale to Alfasigma, according to analysts.
Shareholder Alert: Ademi LLP investigates whether Intercept Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Alfasigma
/PRNewswire/ -- Ademi LLP is investigating Intercept (Nasdaq: ICPT) for possible breaches of fiduciary duty and other violations of law in its transaction with...
Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases
Proposed all-cash acquisition will materially expand Alfasigma’s portfolio in gastroenterology and hepatology and its presence in the U.S....